Abstract
There currently is debate regarding whether U.S. institutions and clinicians may or should restrict patient access to COVID-19 drugs and vaccines that have been granted emergency use authorization by the U.S. Food and Drug Administration. The authors provide their views on the legal, ethical, and clinical ramifications of such restriction.
All Keywords
【초록키워드】 COVID-19, Vaccine, drug, Emergency use authorization, Patient, food, U.S. Food and Drug Administration, clinician, debate, restrict, 【제목키워드】 clinical, Impact, Emergency, obligation,
【초록키워드】 COVID-19, Vaccine, drug, Emergency use authorization, Patient, food, U.S. Food and Drug Administration, clinician, debate, restrict, 【제목키워드】 clinical, Impact, Emergency, obligation,
{{{ 추상적인 }}}
현재 미국 기관과 임상의가 미국 식품의약국(FDA)에서 긴급 사용 승인을 받은 COVID-19 약물 및 백신에 대한 환자의 접근을 제한해야 하는지 여부에 대한 논쟁이 있습니다. 저자는 그러한 제한의 법적, 윤리적, 임상적 결과에 대한 견해를 제공합니다.